{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:18Z","timestamp":1787020818477,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["15-1-401"],"award-info":[{"award-number":["15-1-401"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with incomplete systemic lupus erythematosus (iSLE) have lupus features, but do not meet classification criteria for SLE. Type I interferons (IFN) are important early mediators in SLE, and IFN upregulation in incomplete SLE may be associated with progression to SLE. Since many patients present with skin symptoms, the aim of this study is to investigate IFN type I expression and IFN-related mediators in the blood and skin of iSLE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-nine iSLE patients (ANA titer \u2265\u20091:80, symptoms &lt;\u20095\u2009years, \u2265\u20091 objectified clinical criterion), 39 SLE patients with quiescent disease (fulfilling ACR or SLICC criteria, SLEDAI \u22644), and 22 healthy controls were included. IFN signature was measured in whole blood, based on 12 IFN-related genes, using RT-PCR, and IFN-score was calculated. IFN-related mediators myxovirus-resistance protein A (MxA), IFN-\u03b3-induced protein 10 (IP-10), and monocyte chemoattractant protein (MCP-1) were measured using ELISA. IFN type I expression in the unaffected skin was analyzed by immunostaining with MxA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IFN-score was increased in 50% of iSLE patients and 46% of SLE patients and correlated positively with the number of autoantibodies, anti-SSA titer, ESR, and IgG and negatively with C4 in iSLE. Levels of MxA correlated strongly with IFN-score (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Furthermore, MxA expression was found in 29% of unaffected skin biopsies of iSLE and 31% of SLE patients and also correlated with IFN-score (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IFN-score was increased in half of the iSLE patients, and given the correlation with complement and autoantibody diversity, this suggests a higher risk for disease progression. MxA in the blood and unaffected skin correlated strongly with the IFN-score and is possibly an easily applicable marker for IFN upregulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-019-2034-4","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T09:06:14Z","timestamp":1575277574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-5191","authenticated-orcid":false,"given":"Wietske M.","family":"Lambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Doornbos-van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles F.H.","family":"Diercks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"1","key":"2034_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2016-000176","volume":"4","author":"T Aberle","year":"2017","unstructured":"Aberle T, Bourn RL, Chen H, et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med. 2017;4(1):1\u20137. https:\/\/doi.org\/10.1136\/lupus-2016-000176.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"2034_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","volume":"32","author":"Irini Gergianaki","year":"2018","unstructured":"Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018. https:\/\/doi.org\/10.1016\/j.berh.2018.09.004.","journal-title":"Best Practice & Research Clinical Rheumatology"},{"issue":"1","key":"2034_CR3","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1097\/MD.0000000000000267","volume":"94","author":"\u00cd R\u00faa-Figueroa","year":"2015","unstructured":"R\u00faa-Figueroa \u00cd, Richi P, L\u00f3pez-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Med (United States). 2015;94(1):e267. https:\/\/doi.org\/10.1097\/MD.0000000000000267.","journal-title":"Med (United States)"},{"issue":"11","key":"2034_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"AS Cohen","year":"2007","unstructured":"Cohen AS, Tan EM, Mcshane DJ, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 2007;25(11):1271\u20137. https:\/\/doi.org\/10.1002\/art.1780251101.","journal-title":"Arthritis Rheum"},{"key":"2034_CR5","doi-asserted-by":"crossref","unstructured":"Hochberg M. Updating the Anerican College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism. 1997;40(9):1725\u201334.","DOI":"10.1002\/art.1780400928"},{"issue":"8","key":"2034_CR6","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f5n GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2034_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"Martin Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019: doi:https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"2034_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/40.1.89","volume":"40","author":"AJ Swaak","year":"2001","unstructured":"Swaak AJ, van de Brink H, Smeenk RJ, et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001;40(1):89\u201394 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11157147.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2034_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1191\/0961203304lu477oa","volume":"13","author":"CS Hallengren","year":"2004","unstructured":"Hallengren CS, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus. 2004;13(2):85\u20138. https:\/\/doi.org\/10.1191\/0961203304lu477oa.","journal-title":"Lupus."},{"issue":"2","key":"2034_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1191\/096120300678828073","volume":"9","author":"L Vila","year":"2003","unstructured":"Vila L, Mayor A, Valent A, Garc M, Vila S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2003;9(2):110\u20135. https:\/\/doi.org\/10.1191\/096120300678828073.","journal-title":"Lupus."},{"issue":"12","key":"2034_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/ijcp.12466","volume":"68","author":"M. Al Daabil","year":"2014","unstructured":"Al Daabil M, Massarotti EM, Fine A, et al. Development of SLE among \u201cpotential SLE\u201d patients seen in consultation: long-term follow-up. Int J Clin Pract. 2014. https:\/\/doi.org\/10.1111\/ijcp.12466.","journal-title":"International Journal of Clinical Practice"},{"issue":"12","key":"2034_CR12","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK, Type I. Interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459\u201368. https:\/\/doi.org\/10.4049\/jimmunol.1002795.","journal-title":"J Immunol"},{"key":"2034_CR13","doi-asserted-by":"publisher","unstructured":"Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018:1\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213386.","DOI":"10.1136\/annrheumdis-2018-213386"},{"issue":"8","key":"2034_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2358","volume":"8","author":"M Gilliet","year":"2008","unstructured":"Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8(8):594\u2013606. https:\/\/doi.org\/10.1038\/nri2358.","journal-title":"Nat Rev Immunol"},{"key":"2034_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","volume":"204","author":"R Baccala","year":"2005","unstructured":"Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev. 2005;204:9\u201326. https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00252.x.","journal-title":"Immunol Rev"},{"issue":"12","key":"2034_CR16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1136\/ard.2004.033753","volume":"64","author":"MC Dall\u2019Era","year":"2005","unstructured":"Dall\u2019Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692\u20137. https:\/\/doi.org\/10.1136\/ard.2004.033753.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2034_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/sji.12330","volume":"82","author":"N Hagberg","year":"2015","unstructured":"Hagberg N, R\u00f6nnblom L. Systemic lupus erythematosus - a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82(3):199\u2013207. https:\/\/doi.org\/10.1111\/sji.12330.","journal-title":"Scand J Immunol"},{"issue":"5","key":"2034_CR18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci. 2003;100(5):2610\u20135. https:\/\/doi.org\/10.1073\/pnas.0337679100.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2034_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3642","volume":"14","author":"Damien Chaussabel","year":"2014","unstructured":"Chaussabel D, Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol. 2014. https:\/\/doi.org\/10.1038\/nri3642.","journal-title":"Nature Reviews Immunology"},{"issue":"6","key":"2034_CR20","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.38628","volume":"66","author":"Laurent Chiche","year":"2014","unstructured":"Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014. https:\/\/doi.org\/10.1002\/art.38628.","journal-title":"Arthritis & Rheumatology"},{"issue":"7","key":"2034_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/kez078","volume":"58","author":"Erika Huijser","year":"2019","unstructured":"Huijser E, van Helden-Meeuwsen CG, Groot N, et al. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology. 2019;(C):1\u20132. doi:https:\/\/doi.org\/10.1093\/rheumatology\/kez078","journal-title":"Rheumatology"},{"key":"2034_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","volume":"74","author":"R Lu","year":"2016","unstructured":"Lu R, Munroe ME, Guthridge JM, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016;74:182\u201393. https:\/\/doi.org\/10.1016\/j.jaut.2016.06.001.","journal-title":"J Autoimmun"},{"issue":"1","key":"2034_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","volume":"159","author":"L Farkas","year":"2001","unstructured":"Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-\u03b1\/\u03b2-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159(1):237\u201343. https:\/\/doi.org\/10.1016\/S0002-9440(10)61689-6.","journal-title":"Am J Pathol"},{"issue":"2","key":"2034_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12016-013-8403-x","volume":"47","author":"A Kuhn","year":"2014","unstructured":"Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. 2014;47(2):148\u201362. https:\/\/doi.org\/10.1007\/s12016-013-8403-x.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"2034_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1600-0625.2007.00556.x","volume":"16","author":"J Wenzel","year":"2007","unstructured":"Wenzel J, T\u00fcting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol. 2007;16(5):454\u201363. https:\/\/doi.org\/10.1111\/j.1600-0625.2007.00556.x.","journal-title":"Exp Dermatol"},{"issue":"12","key":"2034_CR26","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/art.20798","volume":"50","author":"KA Kirou","year":"2004","unstructured":"Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-\u03b1-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50(12):3958\u201367. https:\/\/doi.org\/10.1002\/art.20798.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2034_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/jir.2012.0079","volume":"33","author":"M Wadhwa","year":"2013","unstructured":"Wadhwa M, Subramanyam M, Goelz S, et al. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-\u03b2. J Interf Cytokine Res. 2013;33(11):660\u201371. https:\/\/doi.org\/10.1089\/jir.2012.0079.","journal-title":"J Interf Cytokine Res"},{"issue":"16","key":"2034_CR28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526\u201333. https:\/\/doi.org\/10.1056\/NEJMoa021933.","journal-title":"N Engl J Med"},{"issue":"1","key":"2034_CR29","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar3258","volume":"13","author":"C Eriksson","year":"2011","unstructured":"Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantap\u00e4\u00e4-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. https:\/\/doi.org\/10.1186\/ar3258.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"2034_CR30","doi-asserted-by":"publisher","first-page":"R174","DOI":"10.1186\/ar3927","volume":"14","author":"NJ Olsen","year":"2012","unstructured":"Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012;14(4):R174. https:\/\/doi.org\/10.1186\/ar3927.","journal-title":"Arthritis Res Ther"},{"key":"2034_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8791629","volume":"2016","author":"NJ Olsen","year":"2016","unstructured":"Olsen NJ, McAloose C, Carter J, et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis. 2016;2016:1\u20139. https:\/\/doi.org\/10.1155\/2016\/8791629.","journal-title":"Autoimmune Dis"},{"issue":"3","key":"2034_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2249.2009.04057.x","volume":"159","author":"QZ Li","year":"2010","unstructured":"Li QZ, Zhou J, Lian Y, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2010;159(3):281\u201391. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04057.x.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"2034_CR33","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1002\/art.22044","volume":"54","author":"X Feng","year":"2006","unstructured":"Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951\u201362. https:\/\/doi.org\/10.1002\/art.22044.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2034_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/ard.2007.074765","volume":"67","author":"M Nikpour","year":"2008","unstructured":"Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(8):1069\u201375. https:\/\/doi.org\/10.1136\/ard.2007.074765.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2034_CR35","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155. https:\/\/doi.org\/10.1186\/ar3895.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"2034_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0961203307078579","volume":"16","author":"JA James","year":"2007","unstructured":"James JA, Kim-howard XR, Bruner BF, et al. With later onset of systemic lupus erythematosus. 2007:401\u2013409. doi:https:\/\/doi.org\/10.1177\/0961203307078579.","journal-title":"Lupus"},{"issue":"6","key":"2034_CR37","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/annrheumdis-2012-202552","volume":"73","author":"NI Maria","year":"2014","unstructured":"Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2014;73(6):1052\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202552.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2034_CR38","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.24803","volume":"60","author":"JW Bauer","year":"2009","unstructured":"Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60(10):3098\u2013107. https:\/\/doi.org\/10.1002\/art.24803.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2034_CR39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/0961203314523869","volume":"23","author":"C Eriksson","year":"2014","unstructured":"Eriksson C, Rantap\u00e4\u00e4-Dahlqvist S. Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus. Lupus. 2014;23(7):691\u20136. https:\/\/doi.org\/10.1177\/0961203314523869.","journal-title":"Lupus."},{"issue":"11","key":"2034_CR40","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","volume":"75","author":"ME Munroe","year":"2016","unstructured":"Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208140.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2034_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/path.1721","volume":"205","author":"J Wenzel","year":"2005","unstructured":"Wenzel J, W\u00f6renk\u00e4mper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435\u201342. https:\/\/doi.org\/10.1002\/path.1721.","journal-title":"J Pathol"},{"issue":"1","key":"2034_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/ard.2007.070359","volume":"67","author":"E Reefman","year":"2008","unstructured":"Reefman E, Kuiper H, Limburg PC, Kallenberg CGM, Bijl M. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann Rheum Dis. 2008;67(1):11\u20138. https:\/\/doi.org\/10.1136\/ard.2007.070359.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-2034-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T20:01:20Z","timestamp":1606766480000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-2034-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2034"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-2034-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research protocol was approved by the Institutional Medical Ethical Committee (METc 2015\/313). All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, no individual details have been provided.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}